Marksans Pharma Limited (NSE:MARKSANS)

Market Cap	102.44B
Revenue (ttm)	24.74B
Net Income (ttm)	3.68B
Shares Out	453.16M
EPS (ttm)	8.13
PE Ratio	27.80
Forward PE	22.25
Dividend	0.60 (0.27%)
Ex-Dividend Date	Sep 17, 2024

Volume	953,386
Average Volume	1,277,633
Open	233.05
Previous Close	232.69
Day's Range	224.30 - 236.80
52-Week Range	130.00 - 358.70
Beta	1.66
RSI	37.41
Earnings Date	Feb 11, 2025

About Marksans Pharma

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, upper respiratory, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamin...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1992
• Employees: 1,141
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: MARKSANS

Financial Performance

In 2023, Marksans Pharma's revenue was 21.77 billion, an increase of 17.56% compared to the previous year's 18.52 billion. Earnings were 3.14 billion, an increase of 17.80%.